CN115315263A - 细胞表面受体结合化合物和缀合物 - Google Patents

细胞表面受体结合化合物和缀合物 Download PDF

Info

Publication number
CN115315263A
CN115315263A CN202180020578.1A CN202180020578A CN115315263A CN 115315263 A CN115315263 A CN 115315263A CN 202180020578 A CN202180020578 A CN 202180020578A CN 115315263 A CN115315263 A CN 115315263A
Authority
CN
China
Prior art keywords
compound
optionally substituted
independently
conjugate
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180020578.1A
Other languages
English (en)
Chinese (zh)
Inventor
B·B·布施
J·T·恩斯特
G·K·帕卡德
J·G·路易斯
E·D·图尔托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Licia Therapeutics
Original Assignee
Licia Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licia Therapeutics filed Critical Licia Therapeutics
Publication of CN115315263A publication Critical patent/CN115315263A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Primary Cells (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180020578.1A 2020-01-10 2021-01-08 细胞表面受体结合化合物和缀合物 Pending CN115315263A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202062959882P 2020-01-10 2020-01-10
US202062959877P 2020-01-10 2020-01-10
US202062959862P 2020-01-10 2020-01-10
US62/959,882 2020-01-10
US62/959,862 2020-01-10
US62/959,877 2020-01-10
US202063043754P 2020-06-24 2020-06-24
US202063043752P 2020-06-24 2020-06-24
US202063043749P 2020-06-24 2020-06-24
US63/043,752 2020-06-24
US63/043,749 2020-06-24
US63/043,754 2020-06-24
PCT/US2021/012846 WO2021142377A2 (en) 2020-01-10 2021-01-08 Cell surface receptor binding compounds and conjugates

Publications (1)

Publication Number Publication Date
CN115315263A true CN115315263A (zh) 2022-11-08

Family

ID=76788318

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180020578.1A Pending CN115315263A (zh) 2020-01-10 2021-01-08 细胞表面受体结合化合物和缀合物

Country Status (9)

Country Link
US (1) US20230158155A1 (https=)
EP (1) EP4087584A4 (https=)
JP (1) JP2023512455A (https=)
KR (1) KR20220144893A (https=)
CN (1) CN115315263A (https=)
AU (1) AU2021206280A1 (https=)
CA (1) CA3167272A1 (https=)
IL (1) IL294564A (https=)
WO (1) WO2021142377A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116023273A (zh) * 2023-03-29 2023-04-28 思合基因(北京)生物科技有限公司 一种新型碳糖苷及其制备方法
CN117924386A (zh) * 2023-12-22 2024-04-26 合肥综合性国家科学中心大健康研究院 Hpa1降解剂及其制备方法和用途
WO2025043931A1 (zh) 2023-09-01 2025-03-06 杭州天龙药业有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12485178B2 (en) 2018-04-09 2025-12-02 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
EP3773727A4 (en) 2018-04-09 2022-05-04 Yale University BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS
US20230097887A1 (en) 2018-04-09 2023-03-30 Yale University Bi-functional Molecules to Degrade Circulating Proteins
KR20220099963A (ko) * 2019-10-10 2022-07-14 예일 유니버시티 세포 수용체를 통한 분자 분해제로서의 조작된 항체
WO2021155317A1 (en) 2020-01-31 2021-08-05 Avilar Therapeutics, Inc. Asgpr-binding compounds for the degradation of extracellular proteins
KR20240017423A (ko) 2021-05-03 2024-02-07 아빌라 테라퓨틱스, 인크. 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물
EP4370157A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
AU2022310346A1 (en) 2021-07-14 2024-01-25 Lycia Therapeutics, Inc. M6pr cell surface receptor binding compounds and conjugates
WO2023028590A1 (en) * 2021-08-27 2023-03-02 Yale University Molecular degraders of extracellular proteins
EP4293785B1 (en) 2021-11-12 2026-03-25 LG Energy Solution, Ltd. Non-aqueous electrolyte solution for lithium secondary battery, and lithium secondary battery comprising same
FR3132634B1 (fr) * 2022-02-15 2025-04-25 Nanomedsyn Composés bifonctionnels ciblant le récepteur du mannose 6-phosphate cation-indépendant
JP2026503462A (ja) * 2023-01-18 2026-01-29 ライシア セラピューティクス， インコーポレイテッド 自己抗体の分解のためのリソソーム標的化二官能性分子
EP4651902A2 (en) * 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Asgpr binding compounds and conjugates
CN120835794A (zh) 2023-01-18 2025-10-24 利西亚治疗公司 M6pr结合化合物和缀合物
FR3146400B1 (fr) * 2023-03-07 2026-01-30 Nanomedsyn Conjugués ciblant le récepteur du mannose 6-phosphate cation-indépendant et le tissu osseux

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247548A1 (en) * 2006-08-31 2010-09-30 Alcon Research, Ltd. Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
US20150094334A1 (en) * 2002-07-16 2015-04-02 Prana Biotechnology Limited 8-hydroxy quinoline derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962573B2 (en) * 2009-07-03 2015-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compounds targeting the cation-independent mannose 6-phosphate receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150094334A1 (en) * 2002-07-16 2015-04-02 Prana Biotechnology Limited 8-hydroxy quinoline derivatives
US20100247548A1 (en) * 2006-08-31 2010-09-30 Alcon Research, Ltd. Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHUNLIANG LIU: "DESIGN, SYNTHESIS AND EVALUATION OF BIVALENT INHIBITORS OF TREHALOSE-6-PHOSPHATE PHOSPHATASE", UNIVERSITY OF NEW MEXICO UNM DIGITAL REPOSITORY, pages 88 *
JUNE RAE MERWIN等: "Targeted Delivery of DNA Using YEE(GalNAcAH)3, a Synthetic Glycopeptide Ligand for the Asialoglycoprotein Receptor", BIOCONJUGATE CHEM., vol. 5, pages 612, XP000484176, DOI: 10.1021/bc00030a017 *
NINGNING YANG等: "HPMA Polymer-Based Site-Specific Delivery of Oligonucleotides to Hepatic Stellate Cells", BIOCONJUGATE CHEM, vol. 20, pages 1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116023273A (zh) * 2023-03-29 2023-04-28 思合基因(北京)生物科技有限公司 一种新型碳糖苷及其制备方法
WO2025043931A1 (zh) 2023-09-01 2025-03-06 杭州天龙药业有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
CN117924386A (zh) * 2023-12-22 2024-04-26 合肥综合性国家科学中心大健康研究院 Hpa1降解剂及其制备方法和用途
CN117924386B (zh) * 2023-12-22 2024-07-12 合肥综合性国家科学中心大健康研究院 Hpa1降解剂及其制备方法和用途

Also Published As

Publication number Publication date
WO2021142377A3 (en) 2021-10-21
EP4087584A2 (en) 2022-11-16
JP2023512455A (ja) 2023-03-27
EP4087584A4 (en) 2024-08-28
US20230158155A1 (en) 2023-05-25
WO2021142377A2 (en) 2021-07-15
CA3167272A1 (en) 2021-07-15
IL294564A (en) 2022-09-01
KR20220144893A (ko) 2022-10-27
AU2021206280A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
CN115315263A (zh) 细胞表面受体结合化合物和缀合物
AU2024200822B2 (en) Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
US20240335544A1 (en) M6pr cell surface receptor binding compounds and conjugates
JP7402807B2 (ja) グリピカン３抗体およびそのコンジュゲート
AU2020274899B2 (en) Antibody drug conjugates
CN112004557A (zh) 类固醇类化合物及其抗体偶联物
CN111601619A (zh) 用于抗体药物偶联物的亲水性连接体
CN112272669A (zh) 横交联吡咯并苯二氮杂*二聚体（pbd）衍生物及其偶联物
CN113905767A (zh) 无痕连接体及其蛋白质偶联物
CN111093707A (zh) 含支链连接体的Tubulysin同系物偶联物
JP2026026483A (ja) 標的化デンドリマー複合体
CN108349960A (zh) 新念珠藻素化合物和缀合物、它们的制备以及它们的治疗用途
WO2024155748A1 (en) M6pr binding compounds and conjugates
TW202434311A (zh) 自穩定連接子軛合物
JP2026502348A (ja) Ａｄｃコンジュゲーションのためのトポイソメラーゼｉ阻害剤のプロドラッグおよびその使用方法
TW202500198A (zh) 生物活性偶聯物、其製備方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination